Under the agreement, AcuCort will receive an upfront payment and milestone payments, revenue from product supply to Kye, and will also be entitled to royalties based on net sales. The agreement represents another important step in AcuCort’s international expansion, it states.

“The agreement gives us a commercial partner with relevant experience and an established presence in the Canadian market, which comprises more than 40 million people. At the same time, the agreement establishes a clear revenue model for AcuCort, with an upfront payment and further revenue opportunities linked to milestones and future sales of Zeqmelit. This is precisely the type of partnership on which our international strategy is based,” says Jonas Jönmark, CEO of AcuCort.

The commercial agreement grants Kye Pharmaceuticals exclusive rights to register, market, distribute and sell Zeqmelit in Canada. The regulatory submission is planned for early 2027. Subject to marketing authorisation from Health Canada, launch is expected in 2028.

Kye Pharmaceuticals

Kye Pharmaceuticals is a Canadian specialty pharmaceutical company with an established presence in market segments relevant to Zeqmelit, including multiple therapies for paediatrics. Since 2024, the company has launched seven innovative prescription pharmaceutical products in Canada, demonstrating its experience in bringing new medicines to the Canadian market.